We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
-0.45%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.57B
AUM Growth
-$289M
Cap. Flow
-$70.1M
Cap. Flow %
-2.72%
Top 10 Hldgs %
55.83%
Holding
95
New
7
Increased
6
Reduced
12
Closed
24

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$265M
2
RLAY icon
Relay Therapeutics
RLAY
+$43.5M
3
FATE icon
Fate Therapeutics
FATE
+$28.3M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$16.3M
5
PMVP icon
PMV Pharmaceuticals
PMVP
+$13.8M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$89.2M
2
ARGX icon
argenx
ARGX
+$51.6M
3
CNTB
Connect Biopharma Holdings
CNTB
+$50.4M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$43.7M
5
FULC icon
Fulcrum Therapeutics
FULC
+$35.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.19%
2 Financials 0.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ERAS icon
76
Erasca
ERAS
$6.3B
– –
-450,000
Closed -$9.55M
FULC icon
77
Fulcrum Therapeutics
FULC
$239M
– –
-1,250,000
Closed -$35.3M
IMMP
78
Immutep
IMMP
$56.3M
– –
-2,500,000
Closed -$9.68M
KNSA icon
79
Kiniksa Pharmaceuticals
KNSA
$5.8B
– –
-290,577
Closed -$3.31M
KURA icon
80
Kura Oncology
KURA
$800M
– –
-1,050,289
Closed -$19.7M
LABD icon
81
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$71M
– –
-15,000
Closed -$3.19M
MRNA icon
82
PUT
Moderna
MRNA
$21.8B
– –
-10,000
Closed -$253K
NAUT icon
83
Nautilus Biotechnolgy
NAUT
$124M
– –
-750,000
Closed -$4.61M
NGNE icon
84
Neurogene
NGNE
$656M
– –
-75,053
Closed -$10.9M
PASG icon
85
Passage Bio
PASG
$14.4M
– –
-96,416
Closed -$19.2M
SNDX icon
86
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-2,287,782
Closed -$43.7M
SPRY icon
87
ARS Pharmaceuticals
SPRY
$509M
– –
-1,675,377
Closed -$16.7M
ACHL
88
DELISTED
Achilles Therapeutics
ACHL
– –
-1,536,016
Closed -$12M
VINC
89
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
– –
-22,500
Closed -$7.28M
TLIS
90
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
– –
-103,400
Closed -$9.69M
MRNS
91
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-2,400,000
Closed -$27.3M
SNCE
92
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
– –
-10,000
Closed -$1.96M
FSTX
93
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-1,751,428
Closed -$12.8M
TPTX
94
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-525,000
Closed -$34.9M
LJPC
95
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-890,700
Closed -$3.55M
1 2 3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Boxer Capital held 95 positions worth $2.57B, down 10% from $2.86B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Boxer Capital's Q4 2021 filing shows 7 new, 6 increased, 12 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 2,200,000 shares worth $246M. The largest sale was BeOne Medicines Ltd, an estimated $89.2M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 98% a quarter earlier, followed by Financials.

  • Boxer Capital's largest Q4 2021 buy was State Street SPDR S&P Biotech ETF: 2,200,000 shares worth $246M.
  • Boxer Capital added most to Relay Therapeutics in Q4 2021, an estimated $43.5M increase.
  • Boxer Capital's biggest Q4 2021 reduction was BeOne Medicines Ltd, cutting an estimated $89.2M.
  • Boxer Capital fully exited argenx in Q4 2021, selling an estimated $51.6M.
  • Boxer Capital's ten largest holdings make up 56% of its $2.57B portfolio in Q4 2021.
  • Boxer Capital opened 7 new positions and closed 24 in Q4 2021.
  • Boxer Capital's portfolio value fell 10% quarter-over-quarter to $2.57B.

Based on Boxer Capital's 13F filing for Q4 2021, filed 14 Feb 2022.